Optimizing Clinical Trials for Exosome & Extra-Cellular Vesicle Therapies & Scaling Manufacturing & Analytical Testing to Accelerate Regulatory Approval, Maximize Investments & De-Risk Platform Development
The exosome therapeutics field is entering a pivotal phase with multiple companies such as Rion Therapeutics and Capricor into later-stage clinical development and progressing beyond phase 1 and 2 trials. This is driving increased regulatory expectations and creating a need to transform exosome therapeutic platforms into scalable, compliant and commercially viable therapies. Navigating this transition requires strong industry alignment across clinical strategy, manufacturing, analytics and regulatory pathways to unlock the next wave of exosome-based therapeutics.
The 8th Exosome-Based Therapeutics Summit is returning to Boston, offering the ideal platform to network with leaders in clinical development and manufacturing to help you streamline your CMC methods, advance into clinical trials and progress your exosome therapeutic to approval.
Attending Companies Include